Herman Sintim, Purdue University
‘Like a hand fitting into a glove’: Purdue-engineered compound designed to treat drug-resistant acute myeloid leukemia
20 juin 2024 10h55 HE | Purdue Research Foundation
WEST LAFAYETTE, Ind., June 20, 2024 (GLOBE NEWSWIRE) -- Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
20 juin 2024 07h00 HE | atai Life Sciences
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of...
HOOP.jpg
Rising expenses hurting Canadians’ finances: women’s retirement security at risk
20 juin 2024 06h00 HE | Healthcare of Ontario Pension Plan
TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Amidst a rising cost of living and persistent interest rates, Canadians’ retirement outlook is particularly bleak, according to the results of the 2024...
Pixalate Releases Q1
Pixalate Releases Q1 2024 Mobile App IVT Trends by IAB App Categories Reports: Global Ad Fraud Rate Hits 22% as $725 Million Intended for ‘Video Gaming’ Apps Spent on Ad Fraud Instead
17 juin 2024 15h02 HE | Pixalate Inc.
LONDON, June 17, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the inaugural Global Mobile App IVT...
Pixalate’s Q1 2024 D
Pixalate’s Q1 2024 Delisted Mobile Apps Report - Apple App Store: Over 99k Apps Delisted
13 juin 2024 10h11 HE | Pixalate Inc.
LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Pixalate Releases Ad
Pixalate Releases Ad Industry’s First Made For Advertising (MFA) Mobile Apps Report: $7.5 Million in Estimated Global Ad Spend Went to Likely MFA Mobile Apps Across Google & Apple App Stores in Q1 2024
12 juin 2024 08h00 HE | Pixalate Inc.
LONDON, June 12, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the Q1 2024 Made For Advertising (MFA)...
nokialogo.png
Nokia Report reveals enterprises are scaling private wireless for additional uses cases and industrial sites
12 juin 2024 03h00 HE | Nokia Oyj
Nokia Report reveals enterprises are scaling private wireless for additional uses cases and industrial sites 45% of the organizations are leveraging private wireless to support more use cases than...
Pixalate Releases Ma
Pixalate Releases Made For Advertising (MFA) Connected TV (CTV) Apps Ad Spend Report: $64 Million in Estimated Global Ad Spend Went to Likely MFA CTV Apps Across Roku, Amazon Fire TV, Apple TV, and Samsung Smart TV in Q1 2024
11 juin 2024 08h05 HE | Pixalate Inc.
LONDON, June 11, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the Q1 2024 Made For Advertising (MFA)...
LPR_Logo_K.png
London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024
10 juin 2024 14h33 HE | London Research and Pharmaceuticals
London Research & Pharmaceuticals Presents Advancement of LRP-661, Their Lead Drug Candidate, at the New Antiepileptic Drug Conference in Madrid, Spain
Qu Biologics.png
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
07 juin 2024 20h18 HE | Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...